Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Vir Biotechnology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 10.45 · gapped above the open, then crossed back over prior close. High/low 10.79 at 4:00 am ET, 10.26 at 10:00 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In 2019, we entered into a Patent License Agreement (the "Vir Bio Agreement") with Vir Bio, granting a non-exclusive license to our Xtend technology for up to two targets.”
FILING10-K0001326732-26-000015cik 0001326732disclosed by XNCR
“We license a number of technologies to form our antibody platform, and we license the PRO-XTEN ® platform from Sanofi and the siRNA technology from Alnylam.”
FILING10-K0001628280-26-010749cik 0001706431
“We license a number of technologies to form our antibody platform, and we license the PRO-XTEN ® platform from Sanofi and the siRNA technology from Alnylam.”
FILING10-K0001628280-26-010749cik 0001706431
“In November 2023, we entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent (TD Cowen), pursuant to which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $300.0 million, through or to TD Cowen, acting as sales agent or principal.”
FILING10-K0001628280-26-010749cik 0001706431
“Concurrently with the execution of the Astellas Agreement, we also entered into the Astellas SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of our common stock for an aggregate purchase price of approximately $75 million, subject to customary closing conditions and the closing of the Astellas Agreement.”
FILING10-K0001628280-26-010749cik 0001706431
“To support global commercialization of the combination of tobevibart and elebsiran for the treatment of CHD, the Company granted Norgine an exclusive commercial license in Europe, Australia and New Zealand.”
FILING10-K0001628280-26-010749cik 0001706431
“Although we have previously recognized revenue from our profit-share related to sotrovimab under our definitive collaboration agreement with GSK executed in June 2020, or the 2020 GSK Agreement, we expect to continue to incur net operating losses for the foreseeable future.”
FILING10-K0001628280-26-010749cik 0001706431
“The decrease in grant revenue for the year ended December 31, 2025 compared to the same period in 2024 was primarily due to lower revenue recognized in accordance with our agreement with BARDA and to a lesser extent, lower revenue recognized from the Gates Foundation.”
FILING10-K0001628280-26-010749cik 0001706431
“The decrease in grant revenue for the year ended December 31, 2025 compared to the same period in 2024 was primarily due to lower revenue recognized in accordance with our agreement with BARDA and to a lesser extent, lower revenue recognized from the Gates Foundation.”
FILING10-K0001628280-26-010749cik 0001706431
Watchlist prices, news filtered to it, and its next report on your desk.
Vir Biotechnology, Inc. has 4 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Vir Biotechnology, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
VIR (Vir Biotechnology, Inc.) has 4 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ALNY −4.80%, in healthcare.